Recruiting
Phase 1

CBD with Morphine

Sponsor:

National Institute on Drug Abuse (NIDA)

Code:

NCT05143424

Conditions

Opioid Use Disorder

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Interventions

Morphine Sulfate

Study Details

Brief summary:

The purpose of this study is to analyze drug-drug interactions of CBD on co-administered Morphine as first step in understanding CBD-opioid interactions.

Conditions

Opioid Use Disorder

Study ID

NCT05143424

Start date

Nov 4, 2021

Status verified date

Mar, 2024

Completion date

Dec 1, 2024

Anticipated

Primary completion date

Sep 1, 2023

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Must understand and provide written informed consent prior to the initiation of any protocol-specific procedures.
  • Males and females 18 to 55 years of age, inclusive.
  • Body mass index (BMI) ranging from 18 to 34 kg/m2, inclusive, and body weight of 56 kg and above.
  • Adequate venous access as assessed by an investigator at screening.
  • No clinically significant concurrent medical conditions determined by medical history, physical examination, clinical laboratory examination, vital signs, and 12-lead ECG.
  • Recreational opioid use (i.e., defined as prescription opioid use for nontherapeutic purposes on at least 3 occasions within the previous year and at least once in the 12 weeks prior to screening), experienced in using opioids of approximately 30 mg morphine equivalents and not seeking treatment for Opioid Use Disorder.
  • If of childbearing potential, a female study subject must agree to use 1 of the accepted contraceptive regimens from at least 30 days prior to the first administration of the study medication, during the study and for at least 30 days after the last dose of the study medication

1. An acceptable method of contraception includes abstinence from heterosexual intercourse or intrauterine device (with or without hormones)
2. OR agrees to use a double barrier method (e.g., condom and spermicide) during the study and for at least 30 days after the last dose of the study medication. Oral contraceptives are prohibited.
3. If a female of non-childbearing potential, she should be surgically sterile (i.e., has undergone compete hysterectomy, bilateral oophorectomy, or tubal ligation) or in a menopausal state (at least 1 year without menses), as confirmed by FSH level.
  • A male study subject must agree to use a double barrier method (e.g., condom and spermicide) and agree to not donate sperm during the study and for at least 90 days after the last dose of the study medication.
  • Agree not to ingest alcohol, drinks containing caffeine >500 mg/day (e.g., Coca Cola®, tea, coffee, etc.), or grapefruit/grapefruit juice or participate in strenuous exercise 72 hours prior to admission through the last blood draw of the study.
  • Able to speak, read, and understand English sufficiently to allow completion of all study assessments.
  • Must be willing and able to abide by all study requirements and restrictions.

Exclusion Criteria:

  • Contact site directly for more information

Study Design

Enrollment

60 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

active comparator: CBD (350 mg)

CBD 350 mg twice per day for 3 days

active comparator: CBD (700 mg)

CBD 700 mg twice per day for 3 days

Interventions

Morphine Sulfate

Morphine sulfate 30 mg tablets as a single dose twice

Primary outcome measure

  • Establish the Maximum Plasma Concentration (Cmax) of morphine when administered orally with and without CBD [ Time Frame: 3 day ]
  • Establish the Area Under the Curve (AUC 0-t) of morphine and its 2 glucuronide conjugates when morphine is administered with and without CBD [ Time Frame: 3 day ]
  • Establish the Area Under the Curve from zero to infinity (AUC 0-inf) of morphine and its 2 glucuronide conjugates when morphine is administered with and without CBD [ Time Frame: 3 day ]

Central Contacts and Locations

Central contacts

Locations

AltaSciences

Recruiting

Overland Park, Kansas, United States, 66212

Contacts

Principal Investigator:

Debra Kelsh, MD

More Information

Sponsor

National Institute on Drug Abuse (NIDA)

Last update posted

Mar 27, 2024

Last verified

Mar, 2024

Keywords

  • Marijuana Abuse
  • Substance-Related Disorders
  • Chemically-Induced Disorders
  • Mental Disorders
  • Central Nervous System Depressants
  • Psychotropic Drugs
  • Neurotransmitter Agents
  • Cannabidiol
  • CBD
  • Morphine
  • Molecular Mechanisms of Pharmacological Action

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by National Institute on Drug Abuse (NIDA) on 2024-03-27.